Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
|
29959987 |
2018 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure.
|
29959987 |
2018 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
|
24535859 |
2014 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
|
24535859 |
2014 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
|
19650993 |
2009 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
|
19650993 |
2009 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
|
16777915 |
2006 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
|
16777915 |
2006 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).
|
16762801 |
2006 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).
|
16762801 |
2006 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.
|
16101196 |
2005 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.
|
16101196 |
2005 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
|
15732037 |
2005 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
|
15860969 |
2005 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
|
15732037 |
2005 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
|
15860969 |
2005 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
|
12628948 |
2003 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
|
12628948 |
2003 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
|
11136700 |
2001 |
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
|
11136700 |
2001 |
Myocardial Failure
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |